Recent administrative actions by the Department of Justice and DEA have moved FDA-approved marijuana products and those under state medical licenses from Schedule I to Schedule III of the Controlled Substances Act, effective April 28, 2026, following a December 2025 executive order directing expedited review. A new hearing on broader rescheduling of all marijuana begins June 29, 2026, with firm procedural deadlines to evaluate the full shift while preserving controls on illicit trafficking. These steps, building on a 2024 proposal and agency rulemaking, represent the primary drivers of trader assessments for completion timelines, with the administrative process and any resulting appeals or adjustments serving as the key variables ahead.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update$758,943 Vol.
June 30
2%
December 31
24%
$758,943 Vol.
June 30
2%
December 31
24%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Binuksan ang Market: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...Recent administrative actions by the Department of Justice and DEA have moved FDA-approved marijuana products and those under state medical licenses from Schedule I to Schedule III of the Controlled Substances Act, effective April 28, 2026, following a December 2025 executive order directing expedited review. A new hearing on broader rescheduling of all marijuana begins June 29, 2026, with firm procedural deadlines to evaluate the full shift while preserving controls on illicit trafficking. These steps, building on a 2024 proposal and agency rulemaking, represent the primary drivers of trader assessments for completion timelines, with the administrative process and any resulting appeals or adjustments serving as the key variables ahead.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update
Mag-ingat sa mga external link.
Mag-ingat sa mga external link.
Mga Madalas na Tanong